Skip to main content
. 2011 Jul 18;121(8):3100–3108. doi: 10.1172/JCI43656

Figure 4. Platinum-based chemotherapeutics downregulate PD-L2 expression on DCs, resulting in enhanced T cell activation.

Figure 4

(A and B) Expression of T cell inhibitory molecules PD-L1 and PD-L2 (light gray, isotype; white, untreated DC; dark gray, platinum-treated DC) and B7-H2/H3/H4 and IDO by DCs exposed to platinum chemotherapy during maturation. A representative experiment is shown. n > 5 for PD-Ls; n = 2 for other inhibitory molecules. (C) MLR with DCs matured in the presence (black bars) or absence (white bars) of 5 μg/ml oxaliplatin in the presence of blocking antibodies against PD-L1, PD-L2, or control immunoglobulin. #P < 0.05, compared with IgG control DCs; **P < 0.01; ***P < 0.001. A representative experiment is shown. n = 3. Data are depicted as mean + SEM.